Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06052956 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses
A Phase 2 study, sponsored by University of Rochester.
- Not yet
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT06052956 is a Phase 2 study that has not yet begun recruiting, run by University of Rochester. The registered enrollment target is 120 participants.
The verdict
NCT06052956, a Phase 2 study, has not yet begun recruiting, sponsored by University of Rochester.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The objective of this Phase 2 study is to evaluate the efficacy of methylene blue photodynamic therapy (MB-PDT) performed at the time of percutaneous abscess drainage for disinfection of deep tissue abscesses. The study includes three arms: (1) MB-PDT at a fixed drug/light dose plus standard of care abscess drainage , (2) MB-PDT at a patient-specific dose determined by pre-treatment optical measurements plus standard of care abscess drainage , and (3) standard of care abscess drainage. The primary endpoint is reduction in time to removal of the drainage catheter.
Interventions
- DRUG Methylene Blue
- DEVICE Insertion of optical fiber
- DRUG Lipid Emulsion
- DEVICE Laser Illumination (pre-defined dose)
- DEVICE Optical Spectroscopy Measurement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-07-15 |
| Est. Completion | 2031-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06052956
The ClinicalTrials.gov registry entry for NCT06052956 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Methylene Blue is the first listed.
NCT06052956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06052956 about?
NCT06052956 is a clinical study titled "Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses". The objective of this Phase 2 study is to evaluate the efficacy of methylene blue photodynamic therapy (MB-PDT) performed at the time of percutaneous abscess drainage for disinfection of deep tissue abscesses. The study includes three arms: (1) MB-PDT at a fixed drug/light dose plus standard of care...
What is the current status of trial NCT06052956?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2026-07-15. Estimated completion is 2031-06-30.
What interventions are being tested in trial NCT06052956?
The interventions under investigation include: Methylene Blue (DRUG), Insertion of optical fiber (DEVICE), Lipid Emulsion (DRUG), Laser Illumination (pre-defined dose) (DEVICE), Optical Spectroscopy Measurement (DEVICE).
Who is sponsoring clinical trial NCT06052956?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.